A clinical trial for a potential vaccine for the novel coronavirus will begin on Monday, with the first participant receiving an experimental dose, The Associated Press reported.

A government official told the AP about the trial, funded by the National Institutes of Health (NIH), on the condition of anonymity, as the key step in the trial has not yet been publicly announced.

The trial is taking place at the Kaiser Permanente Washington Health Research Institute in Seattle, a city at the center of the coronavirus outbreak in the U.S.

ADVERTISEMENT

According to the AP, the trial will start testing 45 young, healthy participants with different doses of the vaccine, which was developed by both the NIH and Moderna Inc. There's reportedly no chance the participants will become infected from the shots, which do not contain the virus itself. Trials will hopefully help scientists observe any potential side effects and pave the way for larger tests.

While this marks a key step in moving toward the creation of a coronavirus vaccine, public health officials have predicted it will take anywhere from a year to 18 months to confirm a vaccine works.

"The answer to containing is public health measures," Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, has said. "We can't rely on a vaccine over the next several months to a year."

President Trump Donald John TrumpObama calls on Senate not to fill Ginsburg's vacancy until after election Planned Parenthood: 'The fate of our rights' depends on Ginsburg replacement Progressive group to spend M in ad campaign on Supreme Court vacancy MORE has been pushing for the speedy creation of a vaccine, which pharmaceutical companies and manufacturers are racing to find.

"We’ve asked them to accelerate whatever they’re doing in terms of a vaccine," Trump told reporters earlier this month.

An initial $8.3 billion bill signed earlier this month to address the coronavirus included more than $3 billion for vaccine research. The House has since passed another series of measures aiming to reduce the economic effects of COVID-19's spread.